San Raffaele Telethon Institute

a leading European gene-therapy research institute exploring epigenetic editing to improve CAR-T cell function (reducing T-cell exhaustion), and in 2026 announced a manufacturing-scale-up collaboration with Cytiva to address gene-therapy production bottlenecks.

Country
Italy
research eu
Coverage
CNEUUS
genome-engineering
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
AffiliationJoint venture between Fondazione Telethon and Ospedale San Raffaeleresearch.hsr.it · sofinnovapartners.com · fondazionetelethon.it
Research focusGene and cell therapy, including gene and epigenetic editing, CAR-T cell engineering, and cancer immunotherapyresearch.hsr.it · fondazionetelethon.it
FacilityProcess Development Laboratory, GLP Test Facility, Vector Integration Core, Immune Core, Clinical Research Unit (including Clinical Hematology Research Unit and Pediatric Clinical Research Unit), SR-Tiget Clinical Labfondazionetelethon.it
GrantERC Consolidator Grants 2024, Armenise-Harvard Foundation grant, From Bed to Bench grant, Horizon Europe-European Innovation Council grant (X-PAND)research.hsr.it · fondazionetelethon.it
Principal staffLuigi Naldini (Director), Alessandro Aiuti (Deputy Director and Head of Research Unit)fondazionetelethon.it
HeadcountApproximately 300 employees total (176 recorded in one source)fondazionetelethon.it

Independent sources: fondazionetelethon.it · research.hsr.it · sofinnovapartners.com

Technologies
NameClusterRisk
Epigenome editinggenome-engineeringHigh

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.